[{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"$5.0 million","newsHeadline":"Addex Receives Additional $2.8 Million from Indivior and Extends Gabab Pam Research Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0.33000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior PLC","highestDevelopmentStatusID":"2","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Signs Five-Year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Johns Hopkins University","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Evotec","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Pasithea Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ P.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Neumora therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Amgen","highestDevelopmentStatusID":"2","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital\u2019s Center for the Neuroscience of Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Funding","leadProduct":"Psychedelic Compounds","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics \/ atai","highestDevelopmentStatusID":"2","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Psychedelic Therapy","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generation Therapies for Mental Health","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Psychedelics-based Therapeutic","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Dalriada Drug Discovery","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dalriada Drug Discovery \/ atai Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Dalriada D.."},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Advances to Next Stage","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Saniona","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Saniona \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Nanovo","sponsor":"BGN Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Nanovo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nanovo \/ BGN Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Nanovo \/ B.."},{"orgOrder":0,"company":"Psylo","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psylo Announces Sponsored Research Agreement with Daiichi Sankyo to Develop Non-hallucinogenic Psychiatric Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Psychiatric Medicine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Psylo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psylo \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Psylo \/ Da.."},{"orgOrder":0,"company":"3Z","sponsor":"biotx.ai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"3Z","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3Z \/ biotx.ai","highestDevelopmentStatusID":"2","companyTruncated":"3Z \/ biotx.."},{"orgOrder":0,"company":"PsychoGenics","sponsor":"SBIR Grant","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"PsychoGenics and Collaborations Pharmaceuticals Awarded a $1 M Grant to Use AI Platforms to Design New Drugs for Mental Health Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"PsychoGenics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PsychoGenics \/ SBIR Grant","highestDevelopmentStatusID":"2","companyTruncated":"PsychoGeni.."},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Res.."},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Res.."},{"orgOrder":0,"company":"Haleon","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"$632.9 million","upfrontCash":"$579.8 million","newsHeadline":"Dr. Reddy's Acquire Nicotinell and Related Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Haleon","amount2":0.63,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.63,"dosageForm":"Troche\/Lozenge","sponsorNew":"Haleon \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"2","companyTruncated":"Haleon \/ D.."}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.
Details :
Through the acquisition, Reddy will leverage the NRT portfolio, which includes Nicotinell (nicotine) in various formats such as lozenges, patches, and gum, across all applicable global market.
Details :
Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating post-traumatic stress disorder (PTSD) and other mental health ...
Details :
Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the companyâ...
Details :
The funding will be used develop and apply machine learning (ML) tools to explore new areas of chemistry, with the ultimate aim of identifying treatments that target novel or multiple aspects of complex n...
Market Place
Reset All
